Results 151 to 160 of about 116,902 (309)

Staging concept for aging management: Definition, mechanism, and coping strategies

VIEW, EarlyView.
We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang, Shixian Liu, Shangyu Du, Xiangran Cui, Bo Chao, Minglei Liu, Minfei Wu   +6 more
wiley   +1 more source

PARP Feldforschungsmodul 9148: Exposé

, 2022
PARP Framework
core   +1 more source

A poli-ADP-riboziláció szerepe a HaCaT sejtek UVB sugárzás okozta sejthalálban

, 2012
A poli-ADP-riboziláció szerepének vizsgálata HaCaT sejtvonalon UVB sugárzás hatására bekövetkező sejthalál során.
Szinai, Mihály
core  

Management of Advanced Prostate Cancer in the Asia‐Pacific Region: Summary of the Asia‐Pacific Advanced Prostate Cancer Symposium 2025

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Summary of the Asia Pacific Advanced Prostate Cancer Symposium 2025, showing disciplines and diversity of participants, discussion topics (high‐risk localized/locally advanced prostate cancer; PSA persistence and recurrence; radioligand therapy; genetics and genomics; bone protection and other aspects of supportive care), key themes, and high‐level ...
Edmund Chiong, Renu Eapen, Nicholas Buchan, Kenneth Chen, Lukman Hakim, Agus Rizal Hamid, Jae‐Young Joung, Ravindran Kanesvaran, Makarand Khochikar, Jason Letran, Bannakij Lojanapiwat, Indranil Mallick, Chi Fai Ng, Pei Ing Ngam, Teng Aik Ong, Jacob Pang, Darren M. C. Poon, Natasha Roberts, Marniza Saad, Shinichi Sakamoto, Jeremy Tey, Sue Ping Thang, Poh Choo Toh, Levent Türkeri, Nguyễn Tuấn Vinh, Alvin Wong, Yao Zhu, ANZUP Cancer Trials Group, Ian D. Davis   +28 more
wiley   +1 more source

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer

, 2019
Xuan Jiang, Weihua Li, Xiaoying Li, Huimin Bai, Zhenyu ZhangDepartment of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People’s Republic of ChinaAbstract: Poly (ADP-ribose) polymerase (PARP) inhibitors
Li W, Li X, Zhang Z, Jiang X, Bai H
core  

Inhibition of HMGA2 Leads to Reduced Cell Proliferation and Increased Apoptosis in Human Embryonal Carcinoma Cell Lines

Andrology, EarlyView.
ABSTRACT Background The most prevalent solid tumors in young men are testicular germ cell tumors (TGCTs), and embryonal carcinoma is the most common subtype among non‐seminomatous germ cell tumors (NSGCTs). Despite the excellent cure rates of cisplatin‐based chemotherapy, resistance develops in 15%–30% of patients with metastatic cancer, which results ...
Marco De Martino, Matteo Lampitto, Alfredo Fusco, Marco Barchi, Francesco Esposito, Paolo Chieffi   +5 more
wiley   +1 more source

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer

, 2018
Ilaria Colombo, Stephanie Lheureux, Amit Manulal Oza Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada Abstract: Rucaparib is a potent small-molecule inhibitor of poly (ADP ...
Colombo I, Oza AM, Lheureux S
core  

Menopausal hormone therapy after ovarian cancer: A 10‐year survival analysis in premenopausal women

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Among premenopausal women surgically treated for ovarian cancer, no difference in 10‐year overall survival was observed between postoperative MHT users and non‐users. Young ovarian cancer survivors should be recommended MHT after surgically induced menopause.
Åsa Ehlin von Kartaschew, Pernilla Dahm‐Kähler, Kenny Rodriguez Wallberg, Erik Holmberg, Angelique Flöter‐Rådestad   +4 more
wiley   +1 more source

Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study. [PDF]

Front Oncol
Lu J, Song X, Zhang C, Zhu Y, Yang H, Li Y.   +5 more
europepmc   +1 more source

Gold nanorods/siRNA complex administration for knockdown of PARP-1: a potential treatment for perinatal asphyxia

, 2018
Valentina Vio,1,2 Ana L Riveros,1 Andrea Tapia-Bustos,2 Carolyne Lespay-Rebolledo,2 Ronald Perez-Lobos,2 Luis Muñoz,3 Paola Pismante,3 Paola Morales,2,4 Eyleen Araya,5 Natalia Hassan,1,6 Mario Herrera-Marschitz,2 Marcelo J Kogan1,7 1Department of
Lespay-Rebolledo C, Araya E, Hassan N, Kogan MJ, Herrera-Marschitz M, Riveros AL, Tapia-Bustos A, Pismante P, Morales P, Perez-Lobos R, Vio V, Muñoz L   +11 more
core